MEN1 and acute myeloid leukemia: In pediatric AML populations, three phase I trials are investigating the use of menin inhibitors: ziftomenib with venetoclax and gemtuzumab (NCT06448013), ziftomenib with fludarabine and cytarabine (NCT06376162), and revumenib in conjunction with chemotherapy (fludarabine, cytarabine, IT methotrexate, or cytarabine and asparaginase, NCT05761171).